The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding.

The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding.
复制标题

DOI:
10.1371/journal.pone.0053313
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Parish W
Parish W
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Sawicka M;Pawlikowski J;Wilson S;Ferdinando D;Wu H;Adams PD;Gunn DA;Parish W

文献摘要

参考文献

相似文献

The validity of the identification and classification of human cancer using antibodies to detect biomarker proteins depends upon antibody specificity. Antibodies that bind to the tumour-suppressor protein p16INK4a are widely used for cancer diagnosis and research. In this study we examined the specificity of four commercially available anti-p16INK4a antibodies in four immunological applications. The antibodies H-156 and JC8 detected the same 16 kDa protein in western blot and immunoprecipitation tests, whereas the antibody F-12 did not detect any protein in western blot analysis or capture a protein that could be recognised by the H-156 antibody. In immunocytochemistry tests, the antibodies JC8 and H-156 detected a predominately cytoplasmic localised antigen, whose signal was depleted in p16INK4a siRNA experiments. F-12, in contrast, detected a predominately nuclear located antigen and there was no noticeable reduction in this signal after siRNA knockdown. Furthermore in immunohistochemistry tests, F-12 generated a different pattern of staining compared to the JC8 and E6H4 antibodies. These results demonstrate that three out of four commercially available p16INK4a antibodies are specific to, and indicate a mainly cytoplasmic localisation for, the p16INK4a protein. The F-12 antibody, which has been widely used in previous studies, gave different results to the other antibodies and did not demonstrate specificity to human p16INK4a. This work emphasizes the importance of the validation of commercial antibodies, aside to the previously reported use, for the full verification of immunoreaction specificity.
DOI: 10.1186/1471-2407-4-58
发表时间: 2004-08-31
期刊: BMC cancer
影响因子: 3.8
作者:
Volgareva G;Zavalishina L;Andreeva Y;Frank G;Krutikova E;Golovina D;Bliev A;Spitkovsky D;Ermilova V;Kisseljov F
通讯作者: Kisseljov F
DOI: 10.1245/s10434-007-9572-8
发表时间: 2007-12-01
影响因子: 3.7
作者:
Melck, Adrienne;Masoudi, Hamid;Wiseman, Sam M.
通讯作者: Wiseman, Sam M.
DOI: 10.1002/ijc.1174
发表时间: 2001-04-15
影响因子: 6.4
作者:
Klaes, R;Friedrich, T;Doeberitz, MV
通讯作者: Doeberitz, MV
DOI: 10.1016/s0169-5002(00)00191-4
发表时间: 2001-02-01
期刊: LUNG CANCER
影响因子: 5.3
作者:
Chen, JT;Chen, YC;Wang, YC
通讯作者: Wang, YC
DOI: 10.1080/00313020500058607
发表时间: 2005-04-01
期刊: PATHOLOGY
影响因子: 4.5
作者:
Dray, M;Russell, P;Cheerala, B
通讯作者: Cheerala, B